Compare IONQ Inc (IONQ) vs Mesoblast Limited (MESO) Price & Performance

IONQ trades at $43.92, up 3.27% today, with a bullish technical signal and strong revenue growth of 287% in Q2 2026. Despite significant net losses and negative margins, the company's backlog surged to $485 million, and it secured a $28 million defense contract extension. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism about its quantum computing leadership.

Outlook: High growth potential in quantum computing with raised 2026 revenue guidance, but profitability remains distant. Risks include heavy cash burn, intense competition, and stock volatility. The stock offers speculative upside for growth investors tolerant of high risk.

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.